Anxiety disorders are common. Research reviewing the evidence puts the lifetime prevalence at approximately 34 per cent in the US, meaning roughly one in three people will meet the criteria for an anxiety disorder at some point in their life.
This is not the occasional nervousness before a job interview or an exam. Anxiety disorders involve persistent, intense fear or worry that does not resolve on its own, and that interferes with daily functioning: work, relationships, sleep, a person's sense of confidence in their own life.
The same research describes anxiety disorders as often chronic. Left untreated, they can persist for years and cause significant impairment to quality of life and everyday functioning.
None of this means anxiety has to be managed alone or endured indefinitely. Cognitive Behavioural Therapy, generally regarded as the leading evidence-based approach, works by helping people identify the thought patterns and avoidance habits that keep anxiety going, and gradually change them.
If you have been managing anxious days by pushing through and assuming this is simply how you are built, it may be worth speaking with a psychologist or your GP. Anxiety disorders are treatable, and support is available. A conversation is usually the first step.
What this review actually covers
This paper is a review: a synthesis of existing research rather than a single new experiment. It looks at anxiety disorders as a group, covering generalized anxiety disorder (GAD, lifetime prevalence 6.2%), social anxiety disorder (13%), and panic disorder with or without agoraphobia (5.2%). Together, anxiety disorders affect approximately 34% of US adults at some point in their lives. Drawing on meta-analyses, which combine results across many trials to produce a more reliable estimate of an effect, the review brings together data on symptoms, screening, and treatment effectiveness.
Anxiety disorders share a set of core features. There is excessive worry, fear of social or performance situations, panic attacks (sudden surges of intense fear), anticipatory anxiety (dread of future anxiety), and avoidance. They also produce genuine physical symptoms: palpitations, shortness of breath, dizziness. This is part of why anxiety so often first surfaces in a GP's consulting room rather than in a mental health setting.
How it's identified, and what actually helps
The review looks at brief screening tools such as the GAD-7, a short questionnaire. Across studies, it correctly identifies people with an anxiety disorder somewhere between 57.6% and 93.9% of the time (sensitivity), and correctly rules out people without one between 61% and 97% of the time (specificity). That spread shows screening tools are useful, but not precise instruments on their own. A proper diagnosis still depends on clinical judgement.
On treatment, two first-line options stand out. For medication, SSRIs (selective serotonin reuptake inhibitors, such as sertraline) and SNRIs (serotonin-norepinephrine reuptake inhibitors, such as extended-release venlafaxine) showed small-to-medium effects compared with placebo. These are expressed as a standardized mean difference, or SMD: a way of measuring how much groups differ, adjusted for variability, where roughly 0.2 counts as small, 0.5 as medium, and 0.8 as large. The review reports SMDs of -0.55 for GAD, -0.67 for social anxiety, and -0.30 for panic disorder, with negative numbers indicating symptom reduction relative to placebo.
Cognitive behavioural therapy, or CBT, is a structured psychotherapy targeting unhelpful thought patterns and avoidance. It had the strongest evidence base of any psychotherapy reviewed. Its effect sizes, measured as Hedges g (a statistic similar to SMD, adjusted for study size), were large for GAD at 1.01, and small-to-medium for social anxiety disorder at 0.41 and panic disorder at 0.39, each compared with placebo conditions. Notably, this held even when CBT was delivered in primary care settings rather than specialist clinics.
Why this matters, and its limits
The review's central point is straightforward: anxiety disorders are common, physically real, and respond to treatments with solid evidence behind them. At the same time, it stresses that no single treatment suits everyone. Choosing between medication and therapy should take into account personal preference, prior treatment history, other physical or mental health conditions, age, and practical matters such as cost and access.
As a review of existing studies rather than new research on any one person, it cannot describe an individual's experience. Effect sizes describe average outcomes across groups, not a guarantee for any particular person.
If anxiety is something you recognise in yourself, speaking with a GP or mental health professional is a reasonable, evidence-backed step to take.